BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX)VaxcyteFinancing

SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00

Related news

PCVXVaxcyte2026-02-02 21:05 EST

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

PCVXVaxcyte2026-01-29 21:07 EST

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

VXRTVaxart2026-04-17 12:30 EST

Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital

GSKGSK plc2025-03-11 15:50 EST

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-11-04 21:05 EST

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-10-09 20:05 EST

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

PCVXVaxcyte2026-10-07 02:49 EST

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 20:28 EST

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVXVaxcyte2026-10-05 10:00 EST

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Stock data

Close
61.92 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States